Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis

Journal of the American College of Cardiology

Volumn 33, Issue 5, 1999, Pages 1400-1407

  Iwasaki, Atsushi ^a   Matsumori, Akira ^a   Yamada, Takehiko ^a   Shioi, Tetsuo ^a   Wang, Weizhong ^a   Ono, Koh ^a   Nishio, Ryosuke ^a   Okada, Masaharu ^a   Sasayama, Shigetake ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRIC OXIDE SYNTHASE; PIMOBENDAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENCEPHALOMYOCARDITIS VIRUS; GENE EXPRESSION; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS MYOCARDITIS;

ANIMALS; CARDIOVIRUS INFECTIONS; CYTOKINES; DISEASE MODELS, ANIMAL; FOLLOW-UP STUDIES; GENE EXPRESSION; HEART; MALE; MAUS ELBERFELD VIRUS; MICE; MICE, INBRED DBA; MYOCARDITIS; MYOCARDIUM; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHODIESTERASE INHIBITORS; POLYMERASE CHAIN REACTION; PYRIDAZINES; RANDOM ALLOCATION; RNA, MESSENGER; SURVIVAL RATE;

EID: 0033117116     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00692-5     Document Type: Article

References (51)

1. Walter M., Liebens I., Goethals H., et al. Pimobendan (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses. Br J Clin Pharmacol. 25:1988;323-329.
2. Renard M., Walter M., Liebens I., et al. Pimobendan (UD-CG 115 BS) in chronic congestive heart failure. Short-term and one-month effects of a new inotropic vasodilating agent. Chest. 93:1988;1159-1164.
3. Hagemeijer F., Brand H.J., Roth W. Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing. J Cardiovasc Pharmacol. 14:1989;302-310.
4. Baumann G., Ningel K., Permanetter B. Cardiovascular profile of UDCG 115 BS-pimobendane and reversibility of catecholamine subsensitivity in severe congestive heart failure secondary to idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol. 13:1989;730-738.
5. Amrinone Multicenter Trial Group , Massie B., Bourassa M., DiBianco R., et al. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation. 71:1985;963-971.
6. Moran J.F., Rad N., Scanlon P.J. Long term survival of class IV heart failure patients treated with oral amrinone. J Clin Pharmacol. 29:1989;494-499.
7. Enoximone Multicenter Trial Group , Uretsky B.F., Jessup M., Konstam M.A., et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation. 82:1990;774-780.
8. PROMISE Study Research Group , Packer M., Carver J.R., Rodeheffer R.J., et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 325:1991;1468-1475.
9. Pimobendan Multicenter Research Group , Kubo S.H., Gollub S., Bourge R., et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: results of a multicenter trial. Circulation. 85:1992;942-949.
10. Sasayama S., Asanoi H., Kihara Y., et al. Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. Heart-Vessels. 9:1994;113-120.
11. 2+ activation and the inotropic effect of pimobendan comparison with milrinone . Circ Res. 63:1988;911-922.
12. Bohm M., Morano I., Pieske B., et al. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res. 68:1991;689-701.
13. Sasayama S. Immune modulation of cardiac function a new frontier . J Cardiac Failure. 1:1995;331-335.
14. Matsumori A., Yamada T., Suzuki H., et al. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 72:1994;561-566.
15. Latini R., Bianchi M., Correale E., et al. Cytokines in acute myocardial infarction selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist . J Cardiovasc Pharmacol. 23:1994;1-6.
16. Ikeda U., Ohkawa F., Seino Y., et al. Serum interleukin 6 levels become elevated in acute myocardial infarction. J Mol Cell Cardiol. 24:1992;579-584.
17. Tashiro H., Shimokawa H., Yamamoto K., et al. Monocyte-related cytokines in acute myocardial infarction. Am Heart J. 130:1995;446-452.
18. Levine B., Kalman J., Mayer L., et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 323:1990;236-241.
19. McMurray J., Abdullah I., Dargie H.J., Shapiro D. Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J. 66:1991;356-358.
20. Dutka D.P., Elborn J.S., Delamere F., et al. Tumour necrosis factor α in severe congestive cardiac failure. Br Heart J. 70:1993;141-143.
21. Matsumori A., Kawai C. An animal model of congestive (dilated) cardiomyopathy dilatation and hypertrophy of the heart in the chronic stage in DBA/2 mice with myocarditis caused by encephalomyocarditis virus . Circulation. 66:1982;355-360.
22. Shioi T., Matsumori A., Sasayama S. Persistent expression of cytokine in the chronic stage of viral myocarditis in mice. Circulation. 94:1996;2930-2937.
23. Finkel M.S., Oddis C.V., Jacob T.D., et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 257:1992;387-389.
24. Ungureanu-Longrois D., Balligand J.L., Kelly R.A., Smith T.W. Myocardial contractile dysfunction in the systemic inflammatory response syndrome role of a cytokine-inducible nitric oxide synthase in cardiac myocytes . J Mol Cell Cardiol. 27:1995;155-167.
25. Matsumori A., Okada I., Shioi T., et al. Inotropic agents differentially inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophage. Life Sci. 59:1996;L121-L5.
26. Green L.C., Wagner D.A., Glogowski J., et al. Analysis of nitrate, nitrite, and [15N]nitrite in biological fluids. Anal Biochem. 126:1982;131-138.
27. Hock C.E., Yin K., Yue G., Wong P.Y. Effects of inhibition of nitric oxide synthase by aminoguanidine in acute endotoxemia. Am J Physiol. 272:1997;H843-H850.
28. Becker-Andre M., Hahlbrock K. Absolute mRNA quantification using the polymerase chain reaction (PCR). A novel approach by a PCR aided transcript titration assay (PATTY). Nucleic Acids Res. 17:1989;9437-9446.
29. Matsui S., Matsumori A., Matoba Y., et al. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-α production. J Clin Invest. 94:1994;1212-1217.
30. Matsui S., Matsumori A., Sasayama S. Vesnarinone prolongs survival and reduces lethality in a murine model of lethal endotoxemia. Life Sci. 55:1994;1735-1741.
31. Senda C., Shibata T., Oiwa Y., et al. Pharmacokinetic studies on pimobendan (UD-CG 115 BS) (I). Absorption, distribution, metabolism and excretion after single administration in rats. Jpn Pharmacol Ther. 20:1992;1669-1684.
32. Matsumori A., Ono K., Sato Y., et al. Differential modulation of cytokine production by drugs implications for therapy in heart failure . J Mol Cell Cardiol. 28:1996;2491-2499.
33. Chodera A., Feller K. Some aspects of pharmacokinetic and biotransformation differences in humans and mammal animals. Int J Clin Pharmacol Biopharm. 16:1978;357-360.
34. Kubota T., McTiernan C.F., Frye C.S., et al. Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. J Card Fail. 3:1997;117-124.
35. Lane J.R., Neumann D.A., Lafond-Walker A., et al. Interleukin 1 or tumor necrosis factor can promote Coxsackie virus-induced myocarditis in resistant B10.A mice. J Exp Med. 175:1992;1123-1129.
36. Yamada T., Matsumori A., Sasayama S. Therapeutic effect of anti-tumor necrosis factor-α antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation. 89:1994;846-851.
37. Pagani F.D., Baker L.S., Hsi C., et al. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-α in conscious dogs. J Clin Invest. 90:1992;389-398.
38. Yokoyama T., Vaca L., Rossen R.D., et al. Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart. J Clin Invest. 92:1993;2303-2312.
39. Kapadia S., Lee J., Torre-Amione G., et al. Tumor necrosis factor-α gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest. 96:1995;1042-1052.
40. Hosenpud J.D., Campbell S.M., Mendelson D.J. Interleukin-1-induced myocardial depression in an isolated beating heart preparation. J Heart Transplant. 8:1989;460-464.
41. Palmer J.N., Hartogensis W.E., Patten M., et al. Interleukin-1β induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture. J Clin Invest. 95:1995;2555-2564.
42. Thaik C.M., Calderone A., Takahashi N., Colucci W.S. Interleukin-1β modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest. 96:1995;1093-1099.
43. Hirota H., Yoshida K., Kishimoto T., Taga T. Continuous activation of gp 130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA. 92:1995;4862-4866.
44. Balligand J.L., Ungureanu-Longrois D., Kelly R.A., et al. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest. 91:1993;2314-2319.
45. Ungureanu-Longrois D., Balligand J.L., Simmons W.W., et al. Induction of nitric oxide synthase activity by cytokines in ventricular myocytes is necessary but not sufficient to decrease contractile responsiveness to β-adrenergic agonists. Circ Res. 77:1995;494-502.
46. Balligand J.L., Ungureanu-Longrois D., Simmons W.W., et al. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. Characterization and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. J Biol Chem. 269:1994;27580-27588.
47. Ungureanu-Longrois D., Balligand J.L., Okada I., et al. Contractile responsiveness of ventricular myocytes to isoproterenol is regulated by induction of nitric oxide synthase activity in cardiac microvascular endothelial cells in heterotypic primary culture. Circ Res. 77:1995;486-493.
48. Wang W.Z., Matsumori A., Yamada T., et al. Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production. Circulation. 95:1997;245-251.
49. Ishiyama S., Hiroe M., Nishikawa T., et al. Nitric oxide contributes to the progression of myocardial damage in experimental autoimmune myocarditis in rats. Circulation. 95:1997;489-496.
50. Hiraoka Y., Kishimoto C., Takada H., et al. Nitric oxide and murine Coxsackie virus B3 myocarditis aggravation of myocarditis by inhibition of nitric oxide synthase . J Am Coll Cardiol. 28:1996;1610-1615.
51. Lowenstein C.J., Hill S.L., Lafond-Walker A., et al. Nitric oxide inhibits viral replication in murine myocarditis. J Clin Invest. 97:1996;1837-1843.